cqvip:The authors evaluated the long- term efficacy and safety of botulinum toxin type A (BTX- A) in poststroke spasticity patients who completed a 12- week placebo- controlled study and received multiple open- label treatments with 200 to 240 U BTX- A for 42 weeks. Significant and sustained improvements were observed for Disability Assessment and Ashworth scores. Adverse events were generally mild. This extension of a doubleblind study demonstrates that repeated treatments of BTX- A significantly improve function and tone in spasticity.
展开▼
